Moderna-14款mRNA疫苗进入临床，新冠突变疫苗开发再传捷报（英文）-2021.4-219页_12mb

Summary of Second Annual Vaccines Day (April 14, 2021)

Core Content

The Second Annual Vaccines Day by Moderna highlighted the company's advancements in mRNA vaccine technology and its potential to revolutionize the vaccine market. The event covered the development, safety, efficacy, and commercialization of Moderna's vaccines, with a particular focus on the Moderna COVID-19 Vaccine (mRNA-1273), as well as future vaccine programs targeting various diseases.

Main Points

• mRNA Platform: Moderna's mRNA technology offers a platform that allows for rapid development and manufacturing of vaccines. It enables the transition from sequence to clinic to approved products in record time, and the company has the capability to produce complex antigens and combination vaccines.

• Speed and Flexibility: The company's platform allows for fast development timelines, as demonstrated by the 11-month timeline to receive emergency use authorization for its COVID-19 vaccine. This speed is attributed to the use of a cell-free manufacturing process and the ability to scale up production efficiently.

• Safety and Efficacy: The safety profile of the Moderna COVID-19 Vaccine was established through extensive clinical trials and real-world data. The vaccine showed high efficacy (94.1% in Phase 3 trials) and a known safety profile 6 weeks post-second dose. There was no association found between the vaccine and cerebral venous sinus thrombosis (CVST) or thrombotic events.

• Clinical Experience: The vaccine demonstrated similar reactogenicity in clinical trials and real-world settings, with common side effects including pain at the injection site, fatigue, headache, and fever. These side effects were generally mild to moderate and transient.

• Commercialization: Moderna has signed agreements with multiple countries and has delivered over 132 million doses globally. The U.S. market has seen significant vaccine distribution, while international scale-up is still approximately one quarter behind the U.S.

• Future Vaccine Programs: Moderna is developing vaccines for a range of diseases including RSV (mRNA-1345), CMV (mRNA-1647), hMPV/PIV3 (mRNA-1653), Zika (mRNA-1893), Nipah virus (mRNA-1215), Epstein-Barr virus (mRNA-1189), and HIV (mRNA-1644 and mRNA-1574). These programs aim to address major unmet medical needs.

• Market Potential: The vaccine market is large and growing, with an estimated value of $35B in 2020. Moderna believes there is a significant commercial opportunity due to the lack of vaccines for many viruses and the potential to improve the efficacy and safety of existing vaccines.

• Public Health Impact: Infectious diseases, including respiratory viruses, have substantial societal and economic costs. Moderna emphasizes the importance of vaccines in reducing these costs and improving public health outcomes.

• Strategic Expansion: Moderna is expanding its commercial presence globally, with a direct presence in strategic markets and partnerships in various regions. The company also plans to increase ethnic diversity in clinical trials to ensure equitable vaccine development.

• Expert Insights: Immunologists expect SARS-CoV-2 to become an endemic virus, highlighting the need for ongoing vaccination and booster programs. Moderna is well-positioned to address variants of concern with its rapid development and manufacturing capabilities.

• Value Proposition: Vaccines offer a clear value proposition beyond healthcare costs, impacting labor productivity, social, economic, political, psychological, and ethical aspects of society.

Key Information

• mRNA-1273: The Moderna COVID-19 Vaccine has been authorized for emergency use in the U.S. for individuals 18 years and older. It has shown high efficacy and a favorable safety profile, with no reported association with CVST or thrombotic events.

• Vaccine Safety: The vaccine's safety profile is based on clinical trial data and real-world monitoring. Common side effects are manageable and typically resolve within a few days.

• Global Impact: Respiratory viruses are a leading cause of global mortality, particularly in children under 2 and the elderly over 65. Moderna aims to address this by developing combination and complex antigen vaccines.

• Commercial Strategy: Moderna has signed agreements with multiple countries and is working on scaling up production to meet global demand. The company is also focused on sustainable growth and a business model that includes independent supply chains and partnerships.

• Future Directions: The company's vaccine strategy emphasizes the development of combination vaccines, vaccines for complex antigens, and vaccines against public health threats. These efforts are supported by a digital approach and AI integration into operations.

Agenda Highlights

• Introduction of mRNA Vaccine Platform: Presented by Stéphane Bancel, CEO.
• Clinical Experience with Moderna’s COVID-19 Vaccine: Presented by Tal Zaks, M.D., Ph.D., CMO.
• Commercial Update on Moderna’s COVID-19 Vaccine: Presented by Corinne Le Goff, Pharm.D., M.B.A., CCO.
• Infectious Disease Vaccine Strategy: Presented by Stephen Hoge, M.D., President.
• Q&A Session: Concluded the event with a question and answer session.

Conclusion

Moderna is well-positioned to lead in the mRNA vaccine market with its innovative platform, rapid development capabilities, and a broad pipeline of vaccines targeting significant public health threats. The company's focus on combination vaccines, complex antigens, and global expansion underscores its commitment to improving vaccine efficacy and safety while addressing unmet medical needs.